Kornimate/medical-research-clean huggingface dataset:
does radioiodine treatment prevent atrial fibrillation and bone loss in endogenous subclinical hyperthyroidism?

Conditions: Hyperthyroidism

Summary: subclinical hyperthyroidism is defined as the presence of serum free thyroxine (t4) and triiodothyronine (t3) levels within the reference range and a reduced serum thyrotrophin (tsh) level. evidence is accumulating that it has important clinical effects. the substudy is a randomised, dutch multicenter trial to study whether radioiodine treatment prevents the development of atrial fibrillation and prevents decreases in bone mineral density in patients with endogenous subclinical hyperthyroidism.


Eligibility criteria:
inclusion criteria: * subclinical hyperthyroidism \[tsh ≤ 0.1 mu/l, ft4 and t3 within the normal range of the own laboratory (determined 2 times in own laboratory) with an interval of at least 2 months\]. * endogenous cause of subclinical hyperthyroidism limited to autonomous adenoma or multinodular goiter (diagnosis made by the attending physician, based on palpation and the result of a thyroid scintigram). * informed consent. exclusion criteria: * medication with anti-thyroid drugs in the last 3 months (also not allowed during follow-up); thyroid hormone in the last 3 months (allowed during follow-up, but tsh levels should be kept between 0.1 mu/l and the upper limit of normal in the own laboratory); and oral glucocorticoids in the last 3 months (allowed during follow-up when absolutely necessary, but patients in whom glucocorticoids are started cannot be evaluated with respect to changes in bone mineral density \[bmd\]). * radioiodine therapy in the past. * iodine-induced subclinical hyperthyroidism. * pituitary or hypothalamic insufficiency. * pregnancy. * age \<= 40 years. * severe non-thyroidal illness. * drug abuse. * unstable angina pectoris, (history of) atrial fibrillation, (history of) congestive heart failure. * (history of) osteoporotic fracture(s). * patients younger than 70 years of age with a bone mineral density t-score \< - 2.5 standard deviations (sd), or older than 70 years of age with a bone mineral density z-score \< 1.0 sd. (these patients can be randomized but in case it is decided to treat them with anti-osteoporotic drugs they cannot be evaluated with respect to changes in bmd.) * use of betablockers in the last three months. (these patients can be randomised but cannot be evaluated with respect to general and cardiac symptoms. the same applies to patients in whom betablockers are started during follow up.) * other symptoms or signs of hyperthyroidism or obstruction of vital structures which, in the opinion of the attending physician, require active treatment.

Keywords: endogenous subclinical hyperthyroidism
"three dimensional assessment of maxillary molars following distalization using two different approaches"

Conditions: Malocclusion, Angle Class II

Summary: the goal of this controlled clinical trial is to compare the effects of two distalization methods supported by inter-radicular mini-screw for maxillary molars distalization in 20 adult patients with skeletal class i or moderate skeletal class ii malocclusion, dental class ii molar relationship, and full permanent dentition. the participants were randomly selected according to inclusion / exclusion criteria from the outpatient clinic of the department of orthodontics and dentofacial orthopedics, faculty of dentistry, ain shams university, cairo, egypt. selectees age was ranging from 18 to 25 years old. an informed consent has been signed by each patient before his / her enrollment in this study, where the aim , methodology, and possible complications were been clearly described in details. this research has been thoroughly reviewed by the research ethics committee of the faculty of dentistry, ain shams university.

this study is a two-arm, parallel group, prospective randomized clinical trial with the allocation ratio of 1:1. the consolidated standards of reporting trials (consort statement) were used as a guide for this study. after reviewing the study protocol, the ethical committee at the faculty of dentistry, ain-shams university approved the study. before treatment was carried out, a detailed written arabic consent was signed by all the subjects of both groups after full explanation of the aim of the study and the procedures. this prospective clinical study was conducted on a total of 24 maxillary first molars. no financial competing interests: this study was part of a masters' degree in orthodontics, faculty of dentistry, ain-shams university. no financial conflicts of interest were declared. the study was self- funded by the principal investigator. a sample size of 24 distalizing sites was selected and divided into two groups twelve each: group 1: single coil spring. group 2: double coil spring.

Eligibility criteria:
inclusion criteria: 1. all subjects are free from any dental anomalies as well as periodontal and systemic diseases that may influence orthodontic treatment. 2. adult patients with age ranging from 18 to 25 years. 3. full permanent dentition with exclusion of third molars. 4. both first and second maxillary molars are in occlusion. 5. skeletal class i, mild or moderate skeletal class ii malocclusion. 6. full cusp or end to end class ii molar relationship. 7. mild to moderate crowding in the upper dental arch and / or increased overjet. 8. normal or horizontal growth pattern. 9. non-extraction treatment plan. exclusion criteria: 1. previous orthodontic treatment. 2. treatment planning requiring orthognathic surgery. 3. severe molar rotation. 4. poor oral hygiene.

Keywords: dental malocclusion
comparison of cross-cylinder and conventional photorefractive keratectomy(prk) in correcting medium-high astigmatism

Conditions: Astigmatism

Summary: the purpose of this study is to determine whether cross-cylinder approach is more effective than routine method in laser correction of astigmatism.

both eyes of 50 patients(100 eyes) with medium-high compound myopic astigmatism and inclusion criteria,will be treated by photorefractive keratectomy (prk) using excimer laser.it breaks chemical bonds within corneal stroma.it's wavelength is 193 nm that is in the ultraviolets range with high energy and very low tissue penetrance. the right or left eye of every patient would be allocated randomly to one of the study groups using randlist 1.1. in spite of recent advances in excimer laser machines and surgical techniques,correction of astigmatism is not more successful compared to myopia. in this study we will compare two methods of laser correction of astigmatism regarding to visual acuity,residual error and aberrations.

Eligibility criteria:
inclusion criteria: * \>20 years of age * refractive stability for at least one year * regular and symmetric astigmatism of \>1.5 diopters exclusion criteria: * corneal thickness\<470 microns * keratoconus or suspected keratoconus * active ocular disease and systemic collagen disease

Keywords: excimer laser photorefractive keratectomy astigmatism
primary chemotherapy by bcnu-tmz combination in newly diagnosed anaplastic oligodendrocytic tumors: phase ii trial with translational molecular analysis

Conditions: Oligodendroglioma; Oligoastrocytoma

Summary: the first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined with pcv, will be defined by the pending results of phase iii of the eortc. if the phase ii study proposed here achieves its objective, it may help define a new treatment regimen that will be compared to the standard arm from phase iii of the eortc. in addition, this study, by prospectively testing the predictive value of 1p and 19q deletions and of regf amplification, may allow characterization of patients using these markers. if validated, this characterization can constitute a key element in any therapeutic evaluation (patient stratification), and potentially a major tool for medical decision support in these tumors.


Eligibility criteria:
inclusion criteria: * histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma * tumor with measurable contrast enhancement (at least 15 mm in diameter) * surgical procedure limited to a biopsy or partial excision * in the event of partial excision, an early postoperative check-up (\<72 hours) performed at best by mri, if not by ct, is required. * time between surgery and inclusion less than or equal to one and a half months (45 days) * age\> 18 years old; \<70 * karnofsky index\> 60 * stable or reduced dose of corticosteroids in the 15 days prior to inclusion * polynuclear neutrophils\> 1500; platelets\> 100,000 * bilirubin \<1.25 x unl; sgot, sgpt, pal \<2.5 x unl * absence of serious uncontrolled pathology * patient having received and understood the information and having signed the consent exclusion criteria: * presence of gbm foci within the tumor * absence of evaluable residue after surgery * previous chemotherapy or radiotherapy * unsatisfactory expected monitoring conditions * pregnant or breastfeeding woman; lack of effective contraception if of childbearing age * history of malignant disease (with the exception of cis of the cervix and basal cell cancer) * contraindications related to the examination of the i.r.m.

Keywords: chemotherapy bcnu-temozolomide radiotherapy
endobronchial valve in patients with heterogeneous emphysema

Conditions: Chronic Obstructive Pulmonary Disease; Emphysema

Summary: to compare the clinical outcomes of endoscopic lung volume reduction using pulmonx zephyr endobronchial valve (ebv) vs. standard of care (soc) in the treatment of heterogeneous emphysema patients in a controlled trial design setting.

the aim of this prospective, randomized, controlled, one-way crossover study is to assess and compare the efficacy of the zephyr endobronchial valves vs. standard of care (soc) in patients suffering from copd with heterogeneous emphysema. patients will be followed up for 6 months after randomization. patients in the soc arm will crossover to the ebv treatment arm after the 6-month visit and will be followed up for 6 additional months.the primary objective is the variation of fev1 between baseline and 3-month follow-up visit. the secondary objectives will evaluate quality of life, exercise capacity, dyspnea (including bode index) changes, target lobe volume reduction, as well as safety outcomes.

Eligibility criteria:
inclusion criteria: * consent form signed * heterogeneous emphysema on chest ct scanner * intact interlobar fissures adjacent to the target lobe on chest ct or collateral ventilation negative in the target lobe by chartis assessment * post bronchodilator forced expiratory volume in 1 second (fev1) \< 50% predicted * total lung capacity \> 100% predicted * residual volume \> 150% predicted * pao2 \> 45mmhg * post rehabilitation 6 minute walk test \> 140m * no copd exacerbation for at least 6 weeks * stopped cigarette smoking for more than 3 months exclusion criteria: * contraindication to bronchoscopy * tuberculosis, pleural effusion, or clinically significant bronchiectasis * lung carcinoma or pulmonary nodule on ct scan requiring chest ct scan follow-up * active pulmonary infection * prior lung transplant, lvrs, median sternotomy, bullectomy or lobectomy * any extrapulmonary diseases compromising survival or evaluation within the protocol (severe cardiac disease, severe renal insufficiency, cancer...) * inclusion in an other study assessing respiratory treatments * pregnant or lactating woman

Keywords: endobronchial valve
phase i clinical trial of da-6886 in healthy male subjects

Conditions: Irritable Bowel Syndrome

Summary: da-6886_ibs_i is a phase i, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety, tolerability and pharmacokinetics of da-6886 after oral administration in healthy male subjects.


Eligibility criteria:
inclusion criteria: * 20 \~ 45 years old * 27kg/m2 ≥ bmi ≥ 20kg/m2 * healthy male * informed consent exclusion criteria: * clinically significant medical history * smokers * clinically significant hypersensitivity of drugs * clinically significant cutaneous disorder * qtcb \> 450msec * have a history of drug abuse or show positive for drug abuse or cotinine at urine screening
feasibility of continuous sleep recording in patients undergoing deep brain stimulation for parkinson's disease

Conditions: Parkinson Disease

Summary: this pilot study aims to assess a new device designed for an objective measure of sleep parameters. the purpose of the device is to assess, in a more simple and precise way, the impact of deep brain stimulation on patient's sleep.


Eligibility criteria:
inclusion criteria: * patient \> 18 years old * with parkinson disease * scheduled for implantation of electrodes for deep brain stimulation exclusion criteria: * pregnant or breast feeding patient * refusal to participate in the study * patient under legal protection * no health insurance coverage
genomic study for the prediction of efficacy and adverse effects of cd11a monoclonal antibodies(raptiva)

Conditions: Psoriasis

Summary: the pathogenesis of psoriasis has evolved from epidermal hyperproliferation to immune dysregulation in recent years. a th1 cytokine profile is universally found is psoriasis. biologics targeting the immune system have become the focus of study. raptiva (efalizumab) is one of biologics indicated for the treatment of psoriasis, and is the first biologic approved for use in psoriasis in the eu (emea). in usa, it is the second biologic drug (after amevive) for psoriasis. raptiva is a humanized chimeric antibody of cd11a (lfa-1), which blocks the interaction of cd11and icam-1, thus preventing lymphocyte trafficking. it is used for moderate to severe chronic plaque type psoraisis. the first clinical trial of raptiva in asians iscurrently done in the department of dermatology, national taiwan university hospital and the incidence of psoriatic arthritis (either de novo or aggravation of preexisting psoriatic arthritis) is significantly higher than previously reported in western countries（30％ versus 7%，and personal communication with doctors in hong-kong and singapore also reveals a similar safety profile. it seems likely that a racial difference is present. monocytes play a central role in the pathogenesis of psoriatic arthritis. it is thus intriguing to study the pathogenesis of raptiva-induced aggravation of psoriatic arthritis by comparing the difference of monocyes response in the presence of raptiva between patients with and without raptiva-induced psoriatic arthritis. in further study, the cd11a genomic polymorphism will also be investigated. the suudy can provide us with important information on how a novel monoclonal antibody like raptiva can have both therapeutic and detrimental actions on psoriasis. the short term benefit of the study will be in pharmacogenomics and pharmacoeconomics, finding the best candidates for the expensive drug. the long term goal will be the clarification of the pathogenesis of psoriasis and psoriatic arthritis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of psoriasis
the effect of human albumin on coagulation competence and hemorrhage

Conditions: Hemorrhage; Complicating Delivery, Coagulation Defect

Summary: in a randomized clinical trial, the purpose is to investigate if perioperative coagulation and hemorrhage is influenced by colloid or crystalloid.

5% human albumin is used for fluid therapy during surgery. this study evaluate whether affected coagulation competence induced by human albumin leads to a significant perioperative blood loss when compared to administration of lactated ringer´s solution. data are gathered by the investigators, analysed by the sponsor, and remain confidential throughout the process. the investigators shall be involved in all stages of the study development and vouch for the completeness and accuracy of the data. no third part shall influence the protocol, trial conduct, data analysis, or reporting. the investigators will include 40 patients undergoing cystectomy. heart rate, mean arterial pressure, cardiac output are measured after induction of anaesthesia and insertion of the arterial catheter (t0), after establishing normovolaemia but before surgery (t1), after resection of the urinary bladder (t2), at the end of the surgery (t3), and two hours thereafter in the recovery room (t4). arterial blood is drawn for whole blood viscoelastic haemostatic assays to record clot initiation (r-time), formation (maximal amplitude, ma), alpha angle(α) and lysis (ly30) depicting haemostatic competence (thrombelastography). the investigators analyze blood for haemoglobin, creatinine, platelets, and fibrinogen. furthermore, blood is drawn from the central venous catheter for lactate and blood gas variables (abl 825, radiometer, copenhagen, denmark). to avoid excessive administration of human albumin, patients receive lactated ringer´s solution if considered needed after the infusion 25 ml/kg of the allocated fluid (non-study fluid). the fluid balance inclusive the blood loss was calculated after cystectomy, at the end of surgery, and two hours thereafter. the investigators register complications postoperatively inclusive hospital stay until discharge.

Eligibility criteria:
inclusion criteria: * patient more than 18 years old * indication for elective post-renal operation including cystectomy * patient without anticoagulative, acetylsalicylic acid or nonsteroidal antiinflammatory drug treatment for the last 5 days exclusion criteria: * intracerebral bleeding, manifest cardiac insufficient, renal insufficient demanding dialysis, hepatic or coagulation diseases * pregnant or nursing * allergic to human albumin * disturbance in electrolytes * patient under committee * patient joining another trial interfering the actual trial
pressurized cold application for patients total knee prosthesis surgery

Conditions: Knee Prosthesis; Cryotherapy; Pain; Patient Satisfaction

Summary: this study was conducted to examine the effects of pressurized cold applicatıon for patients total knee prosthesis surgery.

the study was conducted as a randomized controlled experimental study in order to determine the effect of pressurized cold application applied after total knee replacement surgery on the level of pain and satisfaction.this study was conducted in 52 patients who applied to pamukkale university hospitals orthopedics and traumatology clinic between july 2019 and february 2020, who met the inclusion criteria and accepted to participate in the study. the patients were divided into 26 in the control group (cold gel) and 26 in the study group (compressed cold therapy bandage) using a simple randomization method. the patients in the control group received 9 cold applications, in the form of 20 minutes of application and 40 minutes of rest after surgery. the patients in the study group were applied 9 cold applications with 30 mmhg pressure for 20 minutes and 40 minutes of rest.

Eligibility criteria:
inclusion criteria: * 18 years and older * tdp surgery is planned to be performed by the same physician according to the rapid recovery protocol * volunteer to participate in research * had no problems in communicating cognitively, emotionally and verbally were included. exclusion criteria: * have a cold allergy * have peripheral vascular disease * diagnosed with raynaud's disease * have cognitive, affective and verbal communication problems
ultrasound to predict the prognosis of rotator cuff tears

Conditions: Rotator Cuff Tear

Summary: to predict the prognosis of large-to-massive rcts and risk of re-tear by ultrasound elastography.

most symptomatic large-to-massiverotator cuff tears (rcts) should be operated, but the prognosis and postoperative risk of re-tear depended on the quality of rotator cuff muscles. preoperative evaluations were usually done by magnetic resonance imaging (mri). mri was used in recent studies to predict the surgical outcome of large-to-massive rcts and postoperative re-tear, but the clinical availability was not as good as ultrasound. the investigators hypothesize that ultrasound elastography can predict the prognosis of large-to-massive rcts and risk of re-tear.

Eligibility criteria:
inclusion criteria: 1. patients who are diagnosed with rotator cuff tear by an orthopedist. 2. the large-to-massive rotator cuff tears need to be confirmed by magnetic resonance imaging or ultrasound. the definitions of this diagnosis include a tear over 3 cm or any full-thickness of tears in more than two rotator cuff muscles. 3. being willing to cooperated with the arranged examinations before the operation. exclusion criteria: 1. patients who are only diagnosed with partial-thickness rotator cuff muscle tears or small- to large- sized full-thickness tears. 2. patients who have acromioclavicular arthritis that needs distal clavicle resection. 3. patients who had serious glenohumeral arthritis, pseudoparalysis, or any other shoulder trauma history.

Keywords: rotator cuff tears surgery ultrasound elastography
atropine in catecholaminergic polymorphic ventricular tachycardia (cpvt)

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia

Summary: to test the hypothesis that increasing the sinus node rate with atropine treatment prior to exercise will reduce exercise-triggered ventricular ectopy compared to baseline in patients with cpvt.

this is a prospective cross-over trial that will enroll eligible patients with cpvt and perform a baseline treadmill exercise tolerance test (ett) followed by a repeat treadmill ett with i.v. atropine administered immediately prior to exercise. atropine is a parasympathetic blocker and results in sinus tachycardia, which is expected to reduce the diastolic interval thereby reducing delayed after depolarizations and ventricular ectopy compared to baseline. both etts will be performed on the same day with two hours of rest scheduled between etts. the primary analysis will be a paired comparison of the number of ventricular ectopic beats recorded during exercise (and recovery) at baseline and following pre-treatment with atropine. secondary endpoints will include the presence of ventricular ectopy (yes/no), complex ventricular ectopy (couplets or greater, yes/no), and the number of runs of complex ventricular ectopy.

Eligibility criteria:
inclusion criteria: * age \>/= 6 years * able to provide written informed consent * clinical diagnosis of cpvt * able to exercise on a treadmill * successful completion of a minimum of 2 exercise stress tests without adverse events exclusion criteria: * contraindication to treadmill stress testing according to vanderbilt university medical center's clinical protocols (unstable angina, decompensated congestive heart failure, severe hypertension (≥ 170/90 mmhg), acute myocardial infarction (\<4 days), moderate to severe aortic stenosis, acute pulmonary embolism, severe pulmonary hypertension, outflow tract obstruction, hypertrophic cardiomyopathy, left main coronary stenosis, left bundle branch block) * females who are pregnant * in the judgement of the investigator, any clinically significant ongoing medical or surgical condition that might jeopardize the subject's safety or interfere with the conduct of the study